These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 8689806)

  • 1. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
    Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
    Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
    Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Buprenorphine abuse: high dose intravenous administration of buprenorphine].
    Varescon I; Vidal-Trécan G; Nabet N; Boissonnas A
    Encephale; 2002; 28(5 Pt 1):397-402. PubMed ID: 12386540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anesthesia for patients on buprenorphine.
    Bryson EO; Lipson S; Gevirtz C
    Anesthesiol Clin; 2010 Dec; 28(4):611-7. PubMed ID: 21074741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.